Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
NCT04365387 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
- Lead sponsor
- Galderma R&D
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 5, 2020
- Completion date
- July 7, 2023
- Enrollment
- 242 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.